Gefitinib, Fluorouracil, Oxaliplatin, and Leucovorin (IFOX) Regimen for Colorectal Cancer.

Michael M Boyiadzis, Hematology-Oncology Therapy ,(2006)

P J Hesketh, M G Kris, S M Grunberg, T Beck, J D Hainsworth, G Harker, M S Aapro, D Gandara, C M Lindley, Proposal for classifying the acute emetogenicity of cancer chemotherapy. Journal of Clinical Oncology. ,vol. 15, pp. 103- 109 ,(1997) , 10.1200/JCO.1997.15.1.103

R de Wit, A C de Boer, G H M vd Linden, G Stoter, A Sparreboom, J Verweij, Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy British Journal of Cancer. ,vol. 85, pp. 1099- 1101 ,(2001) , 10.1054/BJOC.2001.2045

Maria Giulia Zampino, Elena Magni, Cristian Massacesi, Alberto Zaniboni, Angelo Martignetti, Laura Zorzino, Katia Lorizzo, Luigi Santoro, Sabrina Boselli, Filippo de Braud, First clinical experience of orally active epidermal growth factor receptor inhibitor combined with simplified FOLFOX6 as first-line treatment for metastatic colorectal cancer Cancer. ,vol. 110, pp. 752- 758 ,(2007) , 10.1002/CNCR.22851

James Carmichael, H Jan Keizer, Didier Cupissol, Jacques Milliez, Peter Scheidel, Adolf E. Schindler, USE OF GRANISETRON IN PATIENTS REFRACTORY TO PREVIOUS TREATMENT WITH ANTIEMETICS Anti-Cancer Drugs. ,vol. 9, pp. 381- 385 ,(1998) , 10.1097/00001813-199806000-00002

Erick Gamelin, Laurence Gamelin, Laura Bossi, Stefan Quasthoff, Clinical aspects and molecular basis of oxaliplatin neurotoxicity: Current management and development of preventive measures Seminars in Oncology. ,vol. 29, pp. 21- 33 ,(2002) , 10.1016/S0093-7754(02)90017-5

Jörg Thomas Hartmann, Jan Peter Pintoffl, Hendrik Kröning, Carsten Bokemeyer, Martin Holtmann, Thomas Höhler, Gefitinib in combination with oxaliplatin and 5-fluorouracil in irinotecan-refractory patients with colorectal cancer: a phase I study of the Arbeits gemeinschaft Internistische Onkologie (AIO). Onkologie. ,vol. 31, pp. 237- 241 ,(2008) , 10.1159/000122029

Ian E. Smith, , A dose-finding study of granisetron, a novel antiemetic, in patients receiving cytostatic chemotherapy Journal of Cancer Research and Clinical Oncology. ,vol. 119, pp. 350- 354 ,(1993) , 10.1007/BF01208844

Thomas J. Lynch, Daphne W. Bell, Raffaella Sordella, Sarada Gurubhagavatula, Ross A. Okimoto, Brian W. Brannigan, Patricia L. Harris, Sara M. Haserlat, Jeffrey G. Supko, Frank G. Haluska, David N. Louis, David C. Christiani, Jeff Settleman, Daniel A. Haber, Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib The New England Journal of Medicine. ,vol. 350, pp. 2129- 2139 ,(2004) , 10.1056/NEJMOA040938

Justin Floyd, Irfan Mirza, Bradley Sachs, Michael C. Perry, Hepatotoxicity of chemotherapy. Seminars in Oncology. ,vol. 33, pp. 50- 67 ,(2006) , 10.1053/J.SEMINONCOL.2005.11.002